PLANNING FOR A SUCCESSFUL EXIT
2021 June 15
IEEE Entrepreneurs Network – Boston – are all about entrepreneurs!
You are one of them…a dedicated entrepreneur, who has poured heart and sweat into the venture.
Does this focused dedication to launch and grow the business also include planning for potential future exits?
An exit strategy is an important “early on” element of the overall business strategy that describes the vision of how you will eventually capitalize on your investment. The decisions about how you structure and operate the business can have huge implications down the road.
Hear from expert panelists, who have prepared companies and participated in successful exits!
They will talk about exit strategy planning and, just as important, what exits look and feel like in real life to a serial entrepreneur, an investor, and legal M&A advisors. Read More.
7:00 – 7:10 PM – ENET Chairperson’s announcements
7:10 – 7:25 PM – eMinute Pitch – Up to 3 Startup companies’ presentations
7:25 – 8:10 PM – expert speakers on the night’s topic
8:10 – 8:30 PM – Moderator and Audience Q & A with the speakers
8:30 – 9:00 PM – Networking on Grapevine Network
(all times are USA Eastern Daylight time)
A question and answer session will follow the panel discussion, and panelists will be available afterward for responses to individual questions.
Jeff Behrens is a serial biotech entrepreneur. He is currently CEO of GelMEDIX, an ophthalmology startup based on work from Mass Eye and Ear and UCLA. He is also the founder and CEO of LabShares Newton, a biotech incubator for biotech startups run by biotech entrepreneurs.
Formerly, Jeff was President and CEO of Siamab Therapeutics, a biotech company focused on developing antibodies targeting glycan targets in cancer that exited in 2019. Siamab’s lead drug candidate initiated clinical trials in early 2021. Previously, Jeff served as Senior Director, Business Development and Operations at Edimer Pharmaceuticals (funded by Third Rock Ventures) and also worked at Alnylam and Biogen Idec, where co-founded Biogen’s Innovation Incubator.
In 2003 Jeff sold his healthcare IT company, The Telluride Group, to mindSHIFT Technologies, a Fidelity-funded rollup.
Jeff has a Ph.D. from EPFL (Lausanne, Switzerland), an MS from the Harvard/MIT Division of Health Sciences and Technology (HST), an MBA from MIT Sloan, and graduated from Harvard College. He teaches HST590, a Ph.D. level course at MIT.
Mrs. Hill Ritchie has 18 years of investment and financial services experience. She worked internally or as an advisor to 8 family offices directly or through her firm, Private Capital Investments, LLC.
Her current role is Director and Board Member for Nottingham Spirk Family Office, and her past roles include Simon Group Holdings, Eden Capital, and PEX Global. She spent 7 years in Switzerland where she was a Managing Director at Palladio Alternative Research and Senior Analyst and Investment Committee Member for the Saad family office’s $3.5 billion investment portfolio. She was a Director for Wedge Alternatives, and also Hedgefund.net. She is an Angel Investor and is on the investment committee for University Impact, a social impact VC fund.
Katherine received her MBA from Fordham University and her BS in Psychology from the University of Maryland. Her Board member activities include Chair of the ACG New York Family Office Committee, Board Member of ACG NY, and Family Office Advisory Board of TriState Capital. Her past philanthropic volunteer activities include Global Co-Chair of The Guild, the Philanthropy and Education Committees of 100 Women in Finance, Fordham MBA Overseers Board.
Dan Janis is a corporate attorney who focuses on mergers and acquisitions. He also represents public and private companies in a range of general and transactional matters. Dan’s clients rely on his experience in corporate finance, private equity placements, venture capital financings, syndicated commercial credit facilities, joint ventures, and day-to-day business counseling to help them achieve their objectives.
Before joining Davis Malm in 2009, Dan cut his teeth as a corporate associate in the Boston offices of Skadden Arps and Goulston & Storrs. Dan prides himself on his pragmatic, efficient resolution of whatever issues confront his clients.
Dave is a Boston Harbor Angel Investor and intellectual property attorney. He is an active angel investor and advisor to high-tech companies on a range of complex matters. His physics degree from MIT and experience in computer programming, combined with his legal experience, enable him to understand, analyze and provide practical guidance on patent, copyright, trade secret, trademark, licensing, and litigation matters. Dave represents companies with products in a variety of tech markets, from medical devices to computer software to networking to consumer electronics.
Co-Organizer & Moderator
Kristin is an accomplished MedTech executive, serial intrapreneur, investor, and strategic advisor to startups developing biotech solutions. With over 20 years spanning technical, commercial, and business skills as well as Boston Harbor Angel Investor, she covers broad expertise transforming technologies from early concept to successful global divisions.
Kristin holds a B.S. in bioengineering from Syracuse University, MBA in Finance & Marketing from NYU Stern.
Dave is the Founder and CEO of DLH Technology Advisors. He is a startup & Strategy Executive, Innovation Consultant, Advisory Board Member, Connector, Evangelist, and Speaker for growth companies looking to implement, optimize, and fund their Go-to-Market plan.
DLH Technology Advisors offers consulting services including Startup Strategy, & Frameworks, Business Development, Startup Marketing, Go-to-Market Strategy, and Executive Coaching and Startup Funding Channels. DLH has resources for CRM development services including Salesforce implementation, AppExchange App Development, QuickStarts, Lead Architect, and Admin Services for the entire Salesforce product line – www.DLHsales.com.